Elango Vijaykumar, James Gatenby, Alexander Evans, William Henley, Neva Eleangovan, Amy Couper, Margee Kerr, Cono Ariti, John Busby, Luis Alves, Mona Bafadhel, Mohit Bhutani, Victoria Carter, Rongchang Chen, James Chalmers, Michael G Crooks, Graham Devereux, Andrew P Dickens, Daryl Freeman, Chris P Gale, John Martin Gibson, David Halpin, Katherine Hickman, John R Hurst, Jonathan Marshall, Fernando J Martinez, Marc Miravitlles, Hana Mullerova, Tamsin Morris, Shigeo Muro, Jonatan Natman, Jennifer K Quint, Anita Sharma, Dave Singh, Mukesh Singh, Daiana Stolz, Rachel Pullen, Della Varghese, Tom M Wilkinson, Tonya Winders, David Price
{"title":"CONQUEST-ADVANCE: Achieving proDuctiVe implementAtioN of CONQUEST Quality Standards in COPD Care.","authors":"Elango Vijaykumar, James Gatenby, Alexander Evans, William Henley, Neva Eleangovan, Amy Couper, Margee Kerr, Cono Ariti, John Busby, Luis Alves, Mona Bafadhel, Mohit Bhutani, Victoria Carter, Rongchang Chen, James Chalmers, Michael G Crooks, Graham Devereux, Andrew P Dickens, Daryl Freeman, Chris P Gale, John Martin Gibson, David Halpin, Katherine Hickman, John R Hurst, Jonathan Marshall, Fernando J Martinez, Marc Miravitlles, Hana Mullerova, Tamsin Morris, Shigeo Muro, Jonatan Natman, Jennifer K Quint, Anita Sharma, Dave Singh, Mukesh Singh, Daiana Stolz, Rachel Pullen, Della Varghese, Tom M Wilkinson, Tonya Winders, David Price","doi":"10.2147/POR.S601059","DOIUrl":"https://doi.org/10.2147/POR.S601059","url":null,"abstract":"<p><strong>Background: </strong>Integrated COPD management has improved outcomes for patients with diagnosed COPD. The CONQUEST Quality Improvement Program aims to improve the diagnosis and management for patients with potential and diagnosed modifiable high-risk (MHR) COPD, defined as those with a history of exacerbations and opportunities for treatment optimization.</p><p><strong>Methods: </strong>Utilizing the CONQUEST registry and Optimum Patient Care (OPC) Research Database, this observational cohort analysis assessed changes in quality indicator attainment over 12 months among potentially undiagnosed, newly diagnosed and already diagnosed patients with MHR COPD in exposed and matched usual care (UC) general practices. In exposed practices, newly diagnosed and already diagnosed patients were restricted to those receiving OPC-led CONQUEST clinics. Outcomes were compared using difference-in-difference generalized linear models with overlap propensity weighting.</p><p><strong>Findings: </strong>From 168 UK practices, we identified 113,574 potentially undiagnosed (59,706 exposed, 53,868 UC), 2787 newly diagnosed (1448 exposed of which 252 attended OPC clinics, 1339 UC) and 38,054 already diagnosed (21,670 exposed of which 392 attended OPC clinics, 16,384 UC). Potentially undiagnosed patients in exposed practices were more likely to subsequently receive a spirometry-confirmed COPD diagnosis (1.0% vs 0.6%; adjusted ratios-of-risk-ratios [ARRR]:1.55, 95% CI: 1.19-2.01) compared to UC. Initiation or step-up to guideline-appropriate inhaled therapy was more likely among OPC-supported patients in exposed practices for newly diagnosed (96.4% vs 55.7%; ARRR: 1.71, 95% CI: 1.41-2.06) and already diagnosed (91.6% vs 39.8%; ARRR: 1.94, 95% CI: 1.77-2.1212) versus unsupported UC.</p><p><strong>Interpretation: </strong>CONQUEST is associated with measurable improvements in quality indicator attainment aligned with guideline-recommended identification and management of COPD, including higher rates of spirometry-confirmed COPD diagnosis and treatment optimization. Future randomized trials will evaluate if this translates into improved outcomes including reduced exacerbations and hospitalizations.</p>","PeriodicalId":20399,"journal":{"name":"Pragmatic and Observational Research","volume":"17 ","pages":"601059"},"PeriodicalIF":2.9,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149272517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carl Marincowitz, Richard Jacques, Katherine Zwerger, Graham Martin, Karen Spilsbury, Jennifer Kirsty Burton, Fawn Harrad-Hyde, David Price, Emily Lam, Hilary M Garrett, Suzanne Mason
{"title":"Identifying Predictors and Measuring Variation in Anticholinergic Burden and Sedative Load for Older Adult Care Home Residents: A Retrospective Cohort Study Using Routinely Collected Data.","authors":"Carl Marincowitz, Richard Jacques, Katherine Zwerger, Graham Martin, Karen Spilsbury, Jennifer Kirsty Burton, Fawn Harrad-Hyde, David Price, Emily Lam, Hilary M Garrett, Suzanne Mason","doi":"10.2147/POR.S618970","DOIUrl":"https://doi.org/10.2147/POR.S618970","url":null,"abstract":"<p><strong>Purpose: </strong>There over 250,000 care home residents in England and they account for a disproportionate number of hospital admissions. Since 2020, structured medication reviews for care home residents have been mandated in primary care contracts. We used a nationally representative cohort of care home residents to identify predictors of anticholinergic burden and sedative load and measure regional variation in prescribing.</p><p><strong>Patients and methods: </strong>Using primary care data from a third of practices in England we derived four 6-month cohorts of over 40,000 care home residents linked to the national regulator's register of care homes between 01/01/2023 and 31/12/2024. We estimated three-level logistic regression models including resident, postcode district and commissioner (ICB) level factors which predicted high anticholinergic burden and sedative load. We estimated funnel-plots to measure case-mix risk adjusted variation in prescribing at postcode district and commissioner geographical levels.</p><p><strong>Results: </strong>Significant predictors of anticholinergic burden and sedative load included gender, age, frailty, and comorbidity. We demonstrated some case-mix adjusted variation at ICB and postcode district level (anticholinergic burden 2.3-fold ICB and 3.5-fold variation at district level; sedative load 1.7-fold ICB and 2.7-fold variation at District level).</p><p><strong>Conclusion: </strong>This is one of the largest studies of care home residents in England. We have identified factors associated with risk of residents having a high anticholinergic burden or sedative load which could be used to help target personalised interventions.</p>","PeriodicalId":20399,"journal":{"name":"Pragmatic and Observational Research","volume":"17 ","pages":"618970"},"PeriodicalIF":2.9,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13660518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
John L Gore, Allison Thompson, Sneha S Kelkar, Viktor Chirikov, Shweta Kamat, Wenying Quan, Kimberly Donnowitz, Christopher Young, David Nimke, Christina Marie Quicquaro, Candice L Willmon, Priti Pednekar
Athena Gogali, Alexandros Ginis, Maria Bertoli, Polyanthi Papanastasiou, Konstantinos Kostikas
{"title":"Evaluating Satisfaction and Quality of Life with Elpenhaler: A Pooled Analysis of Real-Life Studies.","authors":"Athena Gogali, Alexandros Ginis, Maria Bertoli, Polyanthi Papanastasiou, Konstantinos Kostikas","doi":"10.2147/POR.S626681","DOIUrl":"10.2147/POR.S626681","url":null,"abstract":"<p><strong>Purpose: </strong>Patient adherence and satisfaction are critical for effective asthma and chronic obstructive pulmonary disease (COPD) management, as adherence strongly influences symptoms and prognosis. Patient-reported outcomes, including treatment satisfaction and quality of life, provide valuable insights into the effectiveness of therapeutic interventions from the perspective of individual patients. This study evaluated patient satisfaction with the Elpenhaler device and its impact on quality of life in routine clinical practice.</p><p><strong>Patients and methods: </strong>Individual participant data were pooled from seven real-life studies of fixed-dose combinations delivered via the Elpenhaler device (asthma, budesonide/formoterol: BOREAS, SKIRON, COMPLETE, NOTOS; COPD, salmeterol/fluticasone: AEOLOS, AHEAD, RETRIEVE). Patient satisfaction was assessed with the Feeling of Satisfaction with Inhaler (FSI-10) questionnaire in the four studies in which it was administered, and quality of life in asthma with the mini Asthma Quality of Life Questionnaire (mAQLQ) at baseline, 3 and 6 months. The minimum clinically important difference (MCID) was defined as a change of at least 0.5 units in the mAQLQ total score.</p><p><strong>Results: </strong>In 4333 patients with evaluable FSI-10 score, overall satisfaction was high (mean total score 44.1, standard deviation 5.4), with 94.5% of patients expressing confidence in correct usage. Multivariable analysis showed that age ≥65 years, male sex and lower education level were independently associated with lower satisfaction, whereas never smoking predicted higher satisfaction. In 4212 patients with asthma, mAQLQ total score improved from 4.52 at baseline to 6.06 at 3 months and 6.27 at 6 months; the MCID was achieved by 83.4% and 87.8% of evaluable patients, respectively. Never smoking and lower education level predicted MCID achievement.</p><p><strong>Conclusion: </strong>Treatment delivered via the Elpenhaler is associated with high patient satisfaction and with significant and sustained improvements in quality of life, supporting its effectiveness in real-world respiratory care. The identification of factors associated with satisfaction and quality of life improvement may help in personalising treatment and optimising care.</p>","PeriodicalId":20399,"journal":{"name":"Pragmatic and Observational Research","volume":"17 ","pages":"626681"},"PeriodicalIF":2.9,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149025937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuji Nakatani, Keisuke Masuno, Mao Tanabe, Yuta Nakaniida, Hitoshi Tabuchi
{"title":"Outcomes During a One-Year Multidisciplinary Lifestyle Program in Japanese Specialty Care: A Retrospective Observational Study.","authors":"Yuji Nakatani, Keisuke Masuno, Mao Tanabe, Yuta Nakaniida, Hitoshi Tabuchi","doi":"10.2147/POR.S623362","DOIUrl":"10.2147/POR.S623362","url":null,"abstract":"<p><strong>Background: </strong>Multidisciplinary lifestyle care in routine practice occurs alongside medication changes and irregular testing. We described outcomes during a one-year high-contact specialty-clinic program, separating average post-baseline differences from approximately 12-month change.</p><p><strong>Materials and methods: </strong>This retrospective single-center study included 170 adults with hypertension, dyslipidemia, or diabetes. The primary estimand was the adjusted average difference between baseline and any available post-baseline measurement. Separate linear mixed models included a participant random intercept and fixed terms for follow-up status, age at measurement, sex, and time-varying antidiabetic, antihypertensive, and lipid-lowering medication classes. A complete-pair analysis used the measurement nearest 12 months within a 10-14-month window. Outcome-specific missingness was reported. A Bonferroni benchmark of P<0.0028 was applied across 18 mixed-model outcomes; paired P values were adjusted across all 18 prespecified outcomes.</p><p><strong>Results: </strong>Mean age was 63.0 years (SD 12.6), and 92 participants (54.1%) were women. Body-composition data were nearly complete, whereas physical-function data were available for a selected subset. Differences meeting the multiplicity benchmark were body weight (-2.11 kg, 95% CI -2.68 to -1.54), body fat percentage (-2.04 percentage points, -2.53 to -1.56), waist circumference (-2.72 cm, -3.43 to -2.01), body mass index (-0.90 kg/m<sup>2</sup>, -1.13 to -0.68), 1-min walk (+7.50 steps, 4.51 to 10.49), chair stand (+2.27 repetitions, 1.47 to 3.07), one-leg stand (+7.19 s, 3.37 to 11.00), and low-density lipoprotein cholesterol (-6.44 mg/dL, -10.49 to -2.39). The 10-14-month complete-pair analysis was directionally consistent.</p><p><strong>Conclusion: </strong>During this single-arm program, adiposity measures changed modestly and lower-extremity performance showed larger standardized differences. No comparator, outcome-specific missingness, unknown attendance, and medication-measurement limitations preclude causal attribution.</p>","PeriodicalId":20399,"journal":{"name":"Pragmatic and Observational Research","volume":"17 ","pages":"623362"},"PeriodicalIF":2.9,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148930416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chun-Ting Li, Jin-Zhu Guo, Yu-Ting Zhou, Jing Su, Wen-Hui Wang
{"title":"Effectiveness and Safety of Spesolimab in Adolescents and Adults with Generalized Pustular Psoriasis.","authors":"Chun-Ting Li, Jin-Zhu Guo, Yu-Ting Zhou, Jing Su, Wen-Hui Wang","doi":"10.2147/POR.S608681","DOIUrl":"https://doi.org/10.2147/POR.S608681","url":null,"abstract":"<p><strong>Purpose: </strong>Generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening inflammatory skin disease characterized by widespread erythema, pustules and systemic involvement. Evidence-based treatment guidelines for adolescents with GPP remain limited. Spesolimab, a parenteral humanized monoclonal antibody targeting the interleukin-36 receptor, has emerged as a novel therapeutic option; however, data on its use in adolescents are scarce. Here, we aimed to evaluate the effectiveness of spesolimab in treating GPP episodes in adolescents and compared their outcomes with those in adults.</p><p><strong>Patients and methods: </strong>We analyzed the management of GPP episodes with spesolimab in two adolescent and four adult patients in our unit and conducted a literature review involving 25 patients. Clinical outcomes included response to treatment, pustule resolution, and infection management. Spesolimab achieved rapid and sustained symptom control in all patients, including those with coexisting plaque psoriasis.</p><p><strong>Results: </strong>Twenty-two patients (71.0%) experienced complete pustule resolution within 1 week, and all 31 patients achieved complete pustule resolution by week 4. Treatment responses in adolescents were comparable to those in adults. Infections were identified as key exacerbating factors and managed accordingly.</p><p><strong>Conclusion: </strong>IL-36R inhibitors, such as spesolimab, are potentially effective and safe treatment for both adolescent and adult patients with GPP. Future studies should explore the long-term efficacy of spesolimab and its application strategy of sustained disease control.</p>","PeriodicalId":20399,"journal":{"name":"Pragmatic and Observational Research","volume":"17 ","pages":"608681"},"PeriodicalIF":2.9,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13477177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148766556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Olivia Short, Kaitlyn R McLeod, Kaitlin Erpenbeck, Elizabeth McCamic, Stephanie O Ibemere, Cherise B Harrington, Prateeti Khazanie, Rosa M Gonzalez-Guarda
{"title":"Barriers and Facilitators for Equitable Clinical Research Among Pragmatic Trialists: A Qualitative Study.","authors":"Olivia Short, Kaitlyn R McLeod, Kaitlin Erpenbeck, Elizabeth McCamic, Stephanie O Ibemere, Cherise B Harrington, Prateeti Khazanie, Rosa M Gonzalez-Guarda","doi":"10.2147/POR.S591363","DOIUrl":"10.2147/POR.S591363","url":null,"abstract":"<p><strong>Purpose: </strong>There is a growing urgency to address health inequities in clinical trial design. Pragmatic trials hold promise in addressing inequities in research. We conducted a rapid qualitative analysis of barriers and facilitators to implementing health equity practices in pragmatic trials within the NIH Pragmatic Trials Collaboratory, informed by the DUSON-INFUSE checklist.</p><p><strong>Participants and methods: </strong>A descriptive qualitative design was used to address barriers and facilitators to equitable pragmatic trials. Twelve semi-structured interviews with primary investigators and research associates were conducted. Included trials were selected to represent a variety of phases of funding and study progress to examine the full lifecycle of research. Interview transcripts were summarized using a standardized matrix. Rapid qualitative analysis was implemented to condense data into four emergent themes.</p><p><strong>Results: </strong>Trialists were in the enrollment (n=8), follow-up (n=1), and completion (n=3) phases of their research. Study themes described how (1) funding timelines dictate community relationship building, (2) concordant identities between research teams and study populations promote equity, (3) community alignment on priorities facilitates success, and (4) intervention flexibility is necessary to support participant engagement.</p><p><strong>Conclusion: </strong>To optimize the potential for pragmatic clinical trials to reduce health inequities, all phases of research must be designed with health equity in mind. This includes funding timelines and research budget planning that leave space for relationship building, as well as co-developed priorities between investigators and communities to ensure research fosters trust and engagement.</p>","PeriodicalId":20399,"journal":{"name":"Pragmatic and Observational Research","volume":"17 ","pages":"591363"},"PeriodicalIF":2.9,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13262583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148252886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chris P Gale, Mohit Bhutani, Jeffrey Shi Kai Chan, John Townend, Mehul S Patel, Mohsen Sadatsafavi, William Henley, Cono Ariti, Victoria Carter, Amy Couper, Richard Hubbard, Janwillem W H Kocks, Rachel Pullen, Derek Skinner, David Price
{"title":"Development and Internal Validation of a Prediction Model for Major Cardiovascular and Respiratory Events in Chronic Obstructive Pulmonary Disease: Nationwide Primary Care Electronic Medical Records Cohort Study.","authors":"Chris P Gale, Mohit Bhutani, Jeffrey Shi Kai Chan, John Townend, Mehul S Patel, Mohsen Sadatsafavi, William Henley, Cono Ariti, Victoria Carter, Amy Couper, Richard Hubbard, Janwillem W H Kocks, Rachel Pullen, Derek Skinner, David Price","doi":"10.2147/POR.S551291","DOIUrl":"10.2147/POR.S551291","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular diseases are prevalent in individuals with chronic obstructive pulmonary disease (COPD), but current cardiovascular risk assessment models are not optimised for COPD. We aimed to develop a prediction model for the 10-year risk of major adverse cardiovascular and respiratory events (MACRE) in patients with COPD.</p><p><strong>Methods: </strong>We used nationwide primary care electronic health records from individuals with COPD, aged ≥40 years in 2011 without prior myocardial infarction in the UK Optimum Patient Care Research Database. Practices were randomly divided at the practice level into derivation (80%) and validation (20%) datasets. The primary composite outcome (MACRE) consisted of myocardial infarction, coronary revascularization, heart failure, severe COPD exacerbation, and all-cause mortality. Multivariable Cox regression was used to derive the model using the derivation dataset, with the least absolute shrinkage and selection operator used for variable selection and shrinkage. Performance was evaluated using the validation dataset over prediction horizons of five and 10 years.</p><p><strong>Results: </strong>Among the 122,077 patients included (98,959 in the derivation set; whole cohort: 47.9% women and mean age 69.3 (SD 11.2) years), cardiometabolic risk factors were prevalent, and most had moderate (53.4%) or severe (24.7%) COPD. Over a median follow-up of 10.5 [interquartile range: 4.2-12.4] years, MACRE occurred in 50.2% of the validation set. Sixty-one predictor variables constituted the model, which demonstrated good-to-excellent discrimination and satisfactory calibration across prediction horizons (AUROC 0.78 at five years and 0.82 at 10 years, Brier score of 0.18 at five years and 0.16 at 10 years) in the validation set.</p><p><strong>Conclusion: </strong>A model derived using electronic medical records predicts MACRE in COPD with high discrimination and satisfactory calibration across medium and longer-term prediction horizons. Its utility to inform trial enrolment and clinical decisions requires further study.</p>","PeriodicalId":20399,"journal":{"name":"Pragmatic and Observational Research","volume":"17 ","pages":"551291"},"PeriodicalIF":2.9,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12988761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bernardino Alcázar-Navarrete, Heath Heatley, Alan Kaplan, Lee Tze Tan, Mariko Siyue Koh, Naveed Sattar, John Townend, Derek Skinner, Victoria Carter, David Price
{"title":"The Potential Impact of GLP-1 Receptor Agonists on Exacerbation Risk in Patients with COPD and Type 2 Diabetes: A Real-World Population-Based Observational Study.","authors":"Bernardino Alcázar-Navarrete, Heath Heatley, Alan Kaplan, Lee Tze Tan, Mariko Siyue Koh, Naveed Sattar, John Townend, Derek Skinner, Victoria Carter, David Price","doi":"10.2147/POR.S550543","DOIUrl":"10.2147/POR.S550543","url":null,"abstract":"<p><strong>Introduction: </strong>There is limited evidence on the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with chronic obstructive pulmonary disease (COPD).</p><p><strong>Material and methods: </strong>We conducted a retrospective matched cohort study including patients aged ≥40 years with COPD and T2D. Patients initiating GLP-1 RAs were matched 1:1 with GLP-1 naïve controls based on age, sex, smoking status, COPD treatment (LABA/LAMA/ICS), and exacerbation history. The index date was defined as the first GLP-1 RA prescription, control's index date was a COPD consultation within 186 days of matched patient index. The primary outcome was the number of COPD exacerbations during the 12 months following the index date. Secondary outcomes included oral corticosteroid (OCS) prescriptions and hospital resource utilization (HCRU). Poisson regression models adjusted for BMI and other confounders were used to estimate incidence rate ratios (IRR).</p><p><strong>Results: </strong>A total of 4479 matched patients were included. There were no significant differences between groups in exacerbation rates or OCS use in the year prior to the index date. During follow-up, patients treated with GLP-1 RAs had significantly fewer exacerbations (adjusted IRR [aIRR] 0.84, 95% CI: 0.79-0.89) and fewer OCS prescriptions (aIRR 0.86, 95% CI: 0.77-0.95) compared with controls. A significant delay in time to first OCS prescription was also observed.</p><p><strong>Conclusion: </strong>In this real-world cohort, initiation of GLP-1 RA treatment in patients with COPD and T2D was associated with lower COPD exacerbations and OCS use. These findings suggest a potential role for GLP-1 RAs in modifying the course of COPD in this comorbid population, warranting randomised trials.</p>","PeriodicalId":20399,"journal":{"name":"Pragmatic and Observational Research","volume":"17 ","pages":"550543"},"PeriodicalIF":2.9,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13015956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147521660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christian Schnier, John Busby, Aziz Sheikh, Jennifer K Quint, David B Price, Liam G Heaney
{"title":"Validity of Using Prescription Medications to Classify Disease - A Retrospective Observational Study Using Routinely Collected Electronic Health Records from the UK.","authors":"Christian Schnier, John Busby, Aziz Sheikh, Jennifer K Quint, David B Price, Liam G Heaney","doi":"10.2147/POR.S553011","DOIUrl":"10.2147/POR.S553011","url":null,"abstract":"<p><strong>Background: </strong>Epidemiological studies rely on valid classifications of patients' disease status. However, in the absence of perfect information on every patients' health status, researchers use proxy information with variable and often unknown validity.</p><p><strong>Methods: </strong>To investigate the validity of using prescription records for disease classification, we conducted a retrospective observational study on a UK-wide database of medical prescriptions and clinical records (Optimum Patient Care Research Database). We used electronic health records of 25,000 randomly selected patients for each year between 2004 and 2020 (total N=425,000) and compared disease classification of 18 different chronic conditions based on clinical records for a period of three years (gold standard) with disease classification based on prescription records for the same period. We then used logistic regression to analyse if positive and negative predicted values (PPV and NPV) were associated with known predictors of disease.</p><p><strong>Results: </strong>Results showed large variations in PPV ranging from 8% (heart failure) to 94% (all type diabetes) and smaller variations in NPV ranging from 96% (anxiety) to 100% (Type 1 diabetes). Age, sex, ethnicity, and year but not socio-economic status were associated with variations in validity, especially in classifying dementia, diabetes, and depression.</p><p><strong>Discussion: </strong>Varying validity can partly be explained by different (stratum-specific) prevalence of disease. Additionally, conditions like heart failure can be treated with medication that can also be prescribed for other conditions or can be treated without medication. However, varying validity can also be attributed to imperfect clinical records, which we used as gold standard. As a consequence of low validity, the apparent prevalence based on using prescription records was between 1.3 times lower (all-type diabetes) and up-to 11 times higher (heart failure) than the true prevalence based on the clinical records.</p><p><strong>Conclusion: </strong>Studies using prescription data to classify disease status run a substantial risk of misclassification bias.</p>","PeriodicalId":20399,"journal":{"name":"Pragmatic and Observational Research","volume":"17 ","pages":"553011"},"PeriodicalIF":2.9,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12817061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146019433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}